The emerging class of GLP-1 receptor agonist and GIP dual medications, such as tirzepatide, semaglutide, and the relatively introduced retatrutide, provide significant progress in diabetes control. https://research-grade-peptides427866.soro-blog.com/921611/tirzepatide-one-comparative-review